Acetyl salicylic acid (ASA) is a salicylate with various therapeutic applications due to its several pharmacological activities. In humans, ASA is rapidly hydrolyzed to salicylic acid (SA) by nonspecific enzymes found in many tissues. ASA is eliminated from the body by renal excretion and by hepatic biotransformation to salicyluric acid (SUA) and gentisic acid (GA). ASA dosage is determined by the accumulation of the metabolite SA, which has a longer half-life than ASA and consequently is accumulated in the blood. The rate of formation of SUA is inducible, but its continued induction contributes to the clearance of SA. [1] [2] [3] [4] Some authors have studied the possible pharmacokinetic differences of drugs commonly used in ethnic groups from different places in the world. [5] [6] [7] [8] [9] Mexico has great variety of ethnic groups, approximately 63 different cultures are located in the center, southwest and north of the country, site where flourished great cultures. The Otomies, which inhabit in the Valle del Mezquital and in the State of Mexico in the center of the Mexican Republic, are one of the most important ethnic groups of Mexico.
10) The Mesticians comprises the biggest Spanish-speaking population of Mexico and was formed by a mixture of Europeans and Africans with natives. 11) From the point of view of their genetic characteristics, they could present racial differences as pharmacokinetic profiles as their capabilities for drugs biotransformation. Due to the great importance of indigenous population in our country and their possible pharmacokinetic differences with Mestician population, a study to identify such variations has been started.
This study was conducted to acquire a better understanding of the changes determined by racial influence on the pharmacokinetics of ASA and its metabolites. The objectives of this study were to determine pharmacokinetic differences of ASA and its metabolites in Otomies group with those of Mestician population, and to characterize metabolic pathways of ASA biotransformation in Otomies group.
METHODS
The study was carried out on an indigenous zone named Huehuetla, which is located to the north of the state of Hidalgo, Mexico. Ten healthy Otomies subjects were included and 10 non indigenous subjects (Mestician) as comparative group. Both groups participated in a voluntary way. Subjects included gave their written consent in castellan language or in their dialect, to participate in the study.
The pharmacokinetic study was carried out after the administration of a single dose of aspirin calculated at 15 mg/kg given orally. A fore arm vein canalization was maintained permeable during the study. Blood samples of 2 ml were obtained, one before drug administration and the following at 15, 30 and 60 min and 2, 4, 6, 8, 12 and 24 h after the ingestion. Besides, urine samples were collected during 24 h at intervals of 4 h each one, at 0-4, 5-8, 9-12, 13-16, 17-20, 21-24 h, in order to quantify the cumulative amount of each metabolite excreted. The volume and pH of the plasma and urine samples were measured immediately after collection. Samples were then placed in chilled tubes containing potassium fluoride to prevent rapid hydrolysis and stored at Ϫ20°C until analyzed.
Inclusion Criteria: Healthy Otomies, who voluntary accepted participate were included as study group. A second comparative group of healthy voluntaries (Mestician) were included.
Exclusion Criteria: Those subjects with hepatic and/or renal alterations, with disorders as well as those that were taking another drugs which could interfere with aspirin were excluded for the study.
Elimination Criteria: Those subjects who decided to retire voluntary of the study were eliminated as well as those that by the presence of adverse effects or drug intolerance could not continue with the study.
The method to quantify ASA and its metabolites by HPLC (high-pressure liquid chromatography) was based on previ- The objective of this study was to determine pharmacokinetic differences of acetyl salicylic acid (ASA) and its metabolites: gentisic acid (GA), salicylic acid (SA) and salicyluric acid (SUA) between Otomies and Mesticians healthy subjects. Design. Ten Otomies and 10 Mesticians were included. After a single dose of aspirin given orally (15 mg/kg), blood and urine samples were collected at different times. Results. Pharmacokinetic parameters of salicylates showed significant differences, except distribution volume of SA, and elimination half-life of SUA. Metabolic rates of ASA showed significant differences for all rates between both groups. On the other hand, percentages of dose excreted were more reduced for SA and SUA for the Otomies than for the Mesticians. Conclusion. Results reflect differences in the hydrolysis way i.e. from ASA to SA and aromatic hydroxylation i.e. from SA to GA, which were slower in Otomies subjects, showing a possible pharmacokinetic differences about the capabilities of ASA biotransformation as a consequence of ethnic differences.
ous works 12, 13) and modified by Juárez et al. 14) To 1 ml of plasma, 1 ml of 10% potassium bisulfate, 20 ml of methylparaben solution (1 mg/ml diluted in methanol-water at 10%), and 10 ml of ether-dichloromethane (70 : 30) were added. The tubes were shaken during 2 min and later were centrifuged for 10 min at 4000 rpm. The organic phase was separated and evaporated under nitrogen gas. To 1 ml of urine, 1 ml of oxalic acid 1 M, 20 ml of methylparaben solution (prepared as with plasma samples) and 10 ml of ethyl acetate-hexane (25 : 75) were added. Both plasma and urine samples were filtrated through sep-pack cartridges before the extraction. The evaporation residue of both samples were dissolved with 0.3 ml of methanol-water and 20 ml were injected to chromatographic system, with flow rate of 1.5 ml/min of acetonitrile/water (23 : 77) as mobile phase, and detected at 254 nm, of ultraviolet (UV) detector.
Chromatographic System: Automatic injector Water 712 WISP; Solvent Delivery System Waters model 590; UV detector Waters 490 E of variable wave-length; a column mbondapak C 18 of 39ϫ300 mm; and pick-height ratios of salicylate/IS were used to quantify each compound.
Methylparaben (used as internal standard), ASA, SA, GA, and SUA were purchased from Sigma Chemical Co. (St. Louis, U.S.A.). The assay was calibrated by adding known amounts of ASA, its metabolites and the internal standard. Samples used for calibration contained ASA, SA SUA, and GA in concentrations ranging from 0.512 to 362.0 mmol/l in plasma, and from 1.024 to 362.0 mmol/l in urine; the internal standard was used at a fixed concentration of 13.14 mmol/l. Calibration curves were constructed by plotting the ratio of the peak height of ASA and its metabolites to that of the internal standard (y axis) as function of the concentration of ASA and its metabolites in the samples (x axis).
The accuracy and precision of the method were evaluated by adding known amounts of the drug to duplicated plasma samples over the concentration range used for calibration: percentage recovery of ASA and its metabolites ranged from 92.0 to 98.0% in plasma and from 88.0 to 93.0% in urine. A linear relation between the peak height of ASA and its metabolites and that of the internal standard was found (rϭ0.998). The detection limit for ASA and its metabolites in plasma was 0.256-1.448 mmol/l; in urine, the detection limit ranged from 0.512 to 2.17 mmol/l. Kinetic Analysis After salicylates were measured in both plasma and urine, the values were used to build profiles that described the kinetics of ASA, GA, SUA, and SA by the minimum residual square method. 15) The maximum plasma concentration (C max ) of ASA and its metabolites and the time of peak plasma concentration (t max ) for each subject were derived directly from the original measured values. The terminal log-linear phases of the concentration-time curves of ASA and its metabolites in plasma and urine were identified visually for each subject. The elimination rate constant of drugs represent the process that describe how drug is eliminated from organism, and is represented as k e . The elimination rate constant (k e ) was determined by linear regression analysis of the plot of the natural logarithm of the plasma or urine concentration versus time. 16) Area under the curve (AUC) was calculated by using the trapezoidal rule with extrapolation to infinity by dividing the last measured concentration (at 24 h) by k e . 17, 18) The values were determined to follow first-order kinetics by using and independent model. 15) The amount of ASA and of each metabolite excreted in urine was also calculated. For pharmacokinetic analysis we used Win-nonline Program.
19)
Statistics Results are reported as median values (with ranges) unless indicated otherwise. Significance of differences was estimated by using the Mann-Whitney U test or Student t test. The level of significance was pՅ0.05. Statistical analyses were performed with PAQUEST (version 1.0; Biomedical Software Development, Mexico). 20) 
RESULTS
The group of Otomies was considered for analysis purposes as young adults. We confirmed the authenticity of the Otomies group studied, although they are located in the central zone of Mexican geography. The Otomies were 7 female and 3 male, with 17.5Ϯ0.71 years old (meanϮS.D.), with 48.16Ϯ4.66 kg, and with 1.50Ϯ7.8 m of height. The Mesticians were 6 female and 4 male, with 27.5Ϯ5.21 years old (meanϮS.D.), with 66.9Ϯ12.55 kg and height of 1.62Ϯ 0.09 m. When we made the comparison about demographic data between the two groups, utilizing Student t test for independent samples with pՅ0.05, significant differences were evident in each parameter analyzed.
Pharmacokinetic parameters of ASA and its metabolites in plasma showed significant differences in practically all parameters between the two groups except, to those that refer to distribution volume (Vd) of SA, and elimination half life time (t 1/2 ), of SUA which didn't show significant differences. Statistical analysis was made with Mann Whitney U test, considering pՅ0.05 as significant level (Table 1) .
Metabolic rates of the different metabolites of ASA were found with significant differences for all rates between both groups, however only the metabolic rates of ASA/GA and ASA/GA+SA were significantly lower in Otomi group, as is shown in Table 2 .
Significant differences were found about the amount of GA, SUA and ASA excreted in urine between both groups, however, such differences were found significantly lower in Otomies subjects respect of SA excreted as is shown in Fig.  1 .
DISCUSSION
Acetyl salicylic acid is a salicylate with various therapeutic applications due to its several pharmacological activities. 21) It is used in children as anti-inflammatory agent when suffering from rheumatic fever (RF) or juvenile rheumatoid (JRA). As far as the autoimmune disease as RF as JRA concerned, aspirin remain one of the mainstays of treatment, therefore both the pharmacokinetics and pharmacodynamics of ASA as well as their principal metabolites should be studied. 22, 23) Following ingestion of ASA, it reaches the systemic circulation and is rapidly hydrolyzed to SA, then metabolized by hepatic biotransformation to produce other metabolites by conjugation with glycine to produce SUA and by aromatic hydroxylation to produce GA.
At higher doses, formation and elimination of SUA appears to proceed by Michaelis Menten kinetics, while the rest of the processes follow an apparent first-order kinetics. ASA metabolites like GA, SUA and SA reach plasma levels and residence time in the body considerably; sometimes these parameters are reflected by amounts excreted in urine. 5, 24) There are several reports about SA as therapeutic agent, but not as adverse effects inductor, for which some researchers try to explain if ASA metabolites are implicated in such effects. 21, 24) However, there are not reports with respect to the metabolic way to produce ASA metabolites in ethnic groups. The knowledge of pharmacokinetic of drugs for therapeutic use in different ethnic groups of Mexico, will allow to know the interindividual variability and to consider the differences determined by genetic or environmental factors, in which live an important number of Mexicans that belong to a multiethnic diversity of indigenous origin, as Mestician and Caucasians. Likewise, it will be possible to know the differences with other ethnic groups of different regions of the world. This is of special importance in clinic due to its use in the general population.
Differences observed in the most of pharmacokinetic parameters of each metabolite, implies that biological processes which participate either in the distribution, metabolism or elimination is different among the groups, except for its clinical consequences in those specific cases where there aren't differences neither in Vd of SA nor in t 1/2 of SUA. Due to that ethnic group presented t 1/2 of SA almost double of time respect to control group (9.37 vs. 4.89 h), it is necessary to adjust the dose in this ethnic group.
It is possible to visualize the differences among Otomies vs. Mestician in the metabolic way of ASA (Fig. 2) , being longer the elimination half life of ASA and its metabolites, SA and GA, which showed higher values. These observations reflect differences in the hydrolysis way (from ASA to SA) and aromatic hydroxylation (from SA to GA) which are slower in Otomies subjects. As consequence of longer elimination half life of ASA, SA and GA, as well as their lower clearance in Otomi subjects it made evident a less biotransformation of ASA in this group. On the other hand, percentage of dose excreted was lower for SA and SUA for Otomies. All metabolic rates of ASA and its metabolites showed statistically significant differences between both groups. However, metabolic rates of ASA/GA and ASA/GA+SA were significantly lower in the Otomi group.
All these observations make it necessary to propose studies with larger population groups to confirm the results found here, and try to establish the cause of the differences in metabolic pathways observed, over all in the amounts of each compound excreted in urine. Difference in pharmacokinetic parameters may produce differences in dosage, efficacy and frequencies of adverse effects of ASA between Otomies and Mesticians. This is important, principally because at this stage, the pharmacokinetic characterization of an ethnic group is being established. Observations derived of this study show possible pharmacokinetic differences about capabilities of ASA biotransformation as a consequence of ethnic differences.
